Cell surface phenotype of EBV-T-cell lines from controls and XLP patients
. | CD8 CTL . | . | . | . | . | . | . | . | CD4 CTL . | . | . | . | . | . | . | . | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cell surface marker . | Control . | . | . | . | Patient . | . | . | . | Control . | . | . | . | Patient . | . | . | . | ||||||||||||||
. | C1 . | . | C2 . | . | P1 . | . | P2 . | . | C1 . | . | C2 . | . | P1 . | . | P2 . | . | ||||||||||||||
. | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | ||||||||||||||
CD3 | 95 | 136 | 95 | 227 | 95-98 | 183 | 95-99 | 133 | 99 | 213 | 98-99 | 234 | 97-99 | 300 | 98-99 | 330 | ||||||||||||||
CD4 | 5-15 | 196 | 12-20 | 40 | 7-8 | 26 | 10-12 | 43 | 90-95 | 99 | 85-95 | 102 | 90-95 | 116 | 90-97 | 93 | ||||||||||||||
CD8 | 80-95 | 283 | 85-95 | 232 | 90-95 | 185 | 80-90 | 223 | 5-7 | 2 | 10-15 | 3 | 7-8 | 2 | 5-8 | 2 | ||||||||||||||
CD16 | 3-10 | 2 | 2-5 | 2 | 7-13 | 1 | 10-12 | 1 | 3-4 | 2 | 4-5 | 1 | 2-6 | 1 | 5-7 | 2 | ||||||||||||||
CD56 | 5-15 | 3 | 10-12 | 3 | 8-10 | 3 | 10-12 | 3 | 6-8 | 3 | 3-4 | 3 | 4-8 | 2 | 5-7 | 3 | ||||||||||||||
CD45RA | 2-5 | 3 | 2-5 | 2 | 3-6 | 2.5 | 8-10 | 3 | 1-3 | 6 | 2-3 | 2-4 | 1-2 | 3 | 1-5 | 3 | ||||||||||||||
CD45RO | 90-95 | 71 | 90-97 | 60 | 94-97 | 40 | 90-93 | 51 | 90-97 | 96 | 95-98 | 69 | 98-99 | 79 | 94-99 | 70 | ||||||||||||||
CD28 | < 1 | 3 | < 1 | 2 | 1 | 3 | 1 | 2 | 86-85 | 2 | 70-86 | 2 | 80-87 | 2 | 57-75 | 2 | ||||||||||||||
CD25 | 1-2 | 12 | 3-5 | 3 | 2-3 | 11 | 1-2 | 4 | 85-90 | 21 | 87-92 | 25 | 80-90 | 27 | 85-94 | 21 | ||||||||||||||
CD27 | 30-50 | 1 | 30-55 | 2 | 25-55 | 2 | 20-60 | 2 | 60-70 | 2 | 65-73 | 2 | 55-70 | 2 | 47-73 | 2 | ||||||||||||||
CD69 | 20-70 | 42 | 15-75 | 53 | 20-65 | 56 | 20-55 | 61 | 40-90 | 31 | 35-85 | 28 | 45-85 | 36 | 40-80 | 33 | ||||||||||||||
SLAM | 1-4 | 2 | 2-3 | 3 | 1-4 | 8 | 3-5 | 3 | 1-4 | 2 | 3-4 | 2 | 2-5 | 3 | 3-4 | 3 | ||||||||||||||
2B4 | 40-90 | 27 | 35-95 | 31 | 40-95 | 38 | 30-85 | 41 | 85-90 | 22 | 86-95 | 17 | 80-95 | 23 | 80-97 | 39 | ||||||||||||||
CD95 | 10-13 | 2 | 6-7 | 1 | 7-9 | 1 | 7-15 | 2 | 2-5 | 1 | 3-7 | 2 | 6-7 | 1 | 5-8 | 2 |
. | CD8 CTL . | . | . | . | . | . | . | . | CD4 CTL . | . | . | . | . | . | . | . | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cell surface marker . | Control . | . | . | . | Patient . | . | . | . | Control . | . | . | . | Patient . | . | . | . | ||||||||||||||
. | C1 . | . | C2 . | . | P1 . | . | P2 . | . | C1 . | . | C2 . | . | P1 . | . | P2 . | . | ||||||||||||||
. | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | % . | MFI . | ||||||||||||||
CD3 | 95 | 136 | 95 | 227 | 95-98 | 183 | 95-99 | 133 | 99 | 213 | 98-99 | 234 | 97-99 | 300 | 98-99 | 330 | ||||||||||||||
CD4 | 5-15 | 196 | 12-20 | 40 | 7-8 | 26 | 10-12 | 43 | 90-95 | 99 | 85-95 | 102 | 90-95 | 116 | 90-97 | 93 | ||||||||||||||
CD8 | 80-95 | 283 | 85-95 | 232 | 90-95 | 185 | 80-90 | 223 | 5-7 | 2 | 10-15 | 3 | 7-8 | 2 | 5-8 | 2 | ||||||||||||||
CD16 | 3-10 | 2 | 2-5 | 2 | 7-13 | 1 | 10-12 | 1 | 3-4 | 2 | 4-5 | 1 | 2-6 | 1 | 5-7 | 2 | ||||||||||||||
CD56 | 5-15 | 3 | 10-12 | 3 | 8-10 | 3 | 10-12 | 3 | 6-8 | 3 | 3-4 | 3 | 4-8 | 2 | 5-7 | 3 | ||||||||||||||
CD45RA | 2-5 | 3 | 2-5 | 2 | 3-6 | 2.5 | 8-10 | 3 | 1-3 | 6 | 2-3 | 2-4 | 1-2 | 3 | 1-5 | 3 | ||||||||||||||
CD45RO | 90-95 | 71 | 90-97 | 60 | 94-97 | 40 | 90-93 | 51 | 90-97 | 96 | 95-98 | 69 | 98-99 | 79 | 94-99 | 70 | ||||||||||||||
CD28 | < 1 | 3 | < 1 | 2 | 1 | 3 | 1 | 2 | 86-85 | 2 | 70-86 | 2 | 80-87 | 2 | 57-75 | 2 | ||||||||||||||
CD25 | 1-2 | 12 | 3-5 | 3 | 2-3 | 11 | 1-2 | 4 | 85-90 | 21 | 87-92 | 25 | 80-90 | 27 | 85-94 | 21 | ||||||||||||||
CD27 | 30-50 | 1 | 30-55 | 2 | 25-55 | 2 | 20-60 | 2 | 60-70 | 2 | 65-73 | 2 | 55-70 | 2 | 47-73 | 2 | ||||||||||||||
CD69 | 20-70 | 42 | 15-75 | 53 | 20-65 | 56 | 20-55 | 61 | 40-90 | 31 | 35-85 | 28 | 45-85 | 36 | 40-80 | 33 | ||||||||||||||
SLAM | 1-4 | 2 | 2-3 | 3 | 1-4 | 8 | 3-5 | 3 | 1-4 | 2 | 3-4 | 2 | 2-5 | 3 | 3-4 | 3 | ||||||||||||||
2B4 | 40-90 | 27 | 35-95 | 31 | 40-95 | 38 | 30-85 | 41 | 85-90 | 22 | 86-95 | 17 | 80-95 | 23 | 80-97 | 39 | ||||||||||||||
CD95 | 10-13 | 2 | 6-7 | 1 | 7-9 | 1 | 7-15 | 2 | 2-5 | 1 | 3-7 | 2 | 6-7 | 1 | 5-8 | 2 |
Each determination was carried out on at least 2 occasions.
MFI indicates mean fluorescence intensity.